<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376789</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1501D-3004</org_study_id>
    <nct_id>NCT03376789</nct_id>
  </id_info>
  <brief_title>Mylan Insulin Glargine Study</brief_title>
  <official_title>A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D
      products produced from two manufacturing processes (Process V and Process VI) in combination
      with insulin lispro in patients with type 1 diabetes mellitus (T1DM).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>To test whether MYL-1501D product from Process VI once daily is non-inferior to MYL-1501D product from Process V once daily based on change in HbA1c when administered in combination with mealtime insulin lispro.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>MYL-1501D (Process V Product)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYL-1501D (Process V Product)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MYL-1501D (Process VI Product)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYL-1501D (Process VI Product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYL-1501D</intervention_name>
    <description>Process V or Process VI</description>
    <arm_group_label>MYL-1501D (Process V Product)</arm_group_label>
    <arm_group_label>MYL-1501D (Process VI Product)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written and signed informed consent needs to be provided by subjects or their legal
             representatives before starting any protocol-specific procedures.

          2. Male and female subjects between the ages of 18 to 65 years, both ages inclusive.

          3. Subjects with an established diagnosis of T1DM per ADA 2017 criteria who also fulfil
             the following criteria:

               1. Initiation of insulin treatment within 6 months of T1DM diagnosis

               2. Treatment with basal-bolus insulin therapy for at least 1 year before screening

               3. Fasting plasma C-peptide &lt;0.3 nmol/L at screening

               4. Subject has been on once daily Lantus® at stable dose (±15% variation in dose)
                  for at least 3 months at screening

          4. Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive).

          5. Stable weight, with no more than 5 kg gain or loss in the 3 months prior to screening,
             this information will be collected by subject interview during medical history.

          6. Glycosylated hemoglobin (HbA1c) ≤ 9.5% at screening.

          7. Hemoglobin ≥9.0 g/dL at screening.

          8. Subject has the capability of communicating appropriately with the investigator.

          9. Subject is able and willing to comply with the requirements of the study protocol
             including the 8-point self-monitored blood glucose (SMBG), completion of subject diary
             records and following a recommended diet and exercise plan for the entire duration of
             the study.

         10. Female subjects of childbearing potential who are willing to use oral contraception or
             two acceptable methods of contraception, (e.g., intra-uterine device plus condom,
             spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening
             and for the duration of the study, through study completion.

               1. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation
                  methods) and withdrawal are not acceptable methods of contraception.

               2. Postmenopausal females must have had no regular menstrual bleeding for at least 1
                  year prior to screening.

               3. Female subjects who report surgical sterilization must have had the procedure at
                  least 6 months prior to screening.

               4. All female subjects of childbearing potential must have negative pregnancy test
                  results at screening and at clinic visits, as per the SCHEDULE OF ACTIVITIES
                  (SOA).

               5. If female subjects have male partners who have undergone vasectomy, the vasectomy
                  must have occurred more than 6 months prior to screening

        Exclusion Criteria:

          1. History or presence of a medical condition or disease that in the investigator's
             opinion would place the subject at an unacceptable risk from study participation.

          2. History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analogue preparations used in the study, OR history of significant
             allergic drug reactions.

          3. History of use of animal insulin within the last 3 years or use of approved biosimilar
             insulin glargine at any time prior to study entry, except for subject who previously
             participated in MYL-1501D studies and were compliant with the study protocols.

          4. History of use of a regular immunomodulator therapy in the 1 year prior to screening.

          5. History of autoimmune disorders other than T1DM or insufficiently treated autoimmune
             thyroid disorders judged clinically relevant by the investigator (recorded while
             collecting subject history).

          6. History of ≥1 episodes of diabetic ketoacidosis or emergency room visits for
             uncontrolled diabetes leading to hospitalization within the 6 months prior to
             screening.

          7. History of clinically significant acute bacterial, viral or fungal systemic infections
             in the last 4 weeks prior to screening (recorded while collecting subject history).

          8. Any clinically significant abnormality in electrocardiogram (ECG) or safety laboratory
             tests (LFT, RFT, hematology or any other laboratory deemed clinically relevant by the
             investigator) conducted at screening and considered by the investigator to make the
             subject ineligible for the study.

          9. Serological evidence of human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HbSAg) or hepatitis C antibodies (HCVAb) at screening.

         10. History of drug or alcohol dependence or abuse during the 1 year prior to screening.

         11. Receipt of another investigational drug in the 3 months prior to screening (or as per
             local regulations), or if the screening visit is within 5 half-lives of another
             investigational drug received (whichever is longer), or scheduled to receive another
             investigational drug during the current study period.

         12. Subjects with the following secondary complications of diabetes:

               1. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy
                  examination / retinal photography (performed by a person legally authorized to do
                  so) within the 6 months prior to screening.

               2. Clinical nephrotic syndrome or diabetic nephropathy with a serum creatinine level
                  &gt;1.5 times of upper limit of reference range at screening

               3. History of severe form of neuropathy or cardiac autonomic neuropathy, recorded
                  while collecting subject history. Subject's with mild or moderate forms of
                  neuropathy will be allowed.

               4. Subjects with a history of limb amputation as a complication of diabetes (at any
                  time), or any vascular procedure during the 1 year prior to screening.

               5. History of diabetic foot or diabetic ulcers in the 1 year prior to screening.

         13. Any elective surgery requiring hospitalization planned during the study period.

         14. Clinically significant major organ disorder at the time of screening including:

               1. Uncontrolled hypertension, defined as stage 2 hypertension by Joint National
                  Committee VII (even if therapy is ongoing, blood pressure ≥160 mm Hg systolic or
                  ≥100 mm Hg diastolic).

               2. Uncontrolled hyperlipidemia (even if therapy is ongoing, LDL &gt;160 mg/dL or
                  triglycerides &gt;500 mg/dL).

               3. Uncontrolled hyperthyroidism or hypothyroidism (subjects can be included if these
                  conditions are controlled with thyroid hormones or anti-thyroid drugs).

               4. Impaired hepatic function (alanine transaminase [ALT] or aspartate transaminase
                  [AST] value &gt;2 times the upper limit of the reference range and/or serum
                  bilirubin 1.5 times the upper limit of the reference range at the screening
                  visit). Subjects with evidence of Gilberts disease may be included in the study
                  if they have total bilirubin of &lt;3 mg/dL with indirect bilirubin contributing to
                  &gt;80% of the total bilirubin.

         15. History of a significant medical condition, such as:

               1. Clinically significant cardiac disease like unstable angina, myocardial
                  infarction, grade 3 or 4 congestive heart failure (CHF) according to New York
                  Heart Association criteria, valvular heart disease, cardiac arrhythmia requiring
                  treatment, and pulmonary hypertension; during the year prior to screening.

               2. Stroke or transient ischemic attack (TIA) in the 6 months before screening.

         16. Subjects with major depressive illness in the last 3 years (those who have
             well-controlled depression for 3 months on a stable dose of antidepressants, with no
             major depressive episodes in the last 3 years, can be included, even if they are on
             medication), subjects with history of other severe psychiatric diseases (manic
             depressive psychosis [MDP], schizophrenia), which in the opinion of the investigator
             precludes the subject from participating in the study (recorded while collecting
             subject history).

         17. History of hematological disorders that can affect the reliability of HbA1c estimation
             (hemoglobinopathies, hemolytic anemia, sickle cell anemia, etc.).

         18. Subjects using the following in the 3 months prior to screening:

               1. Insulin pump therapy

               2. Any anti-diabetic drugs other than the study insulins allowed by the protocol.

         19. Moderate insulin resistance, defined as requiring insulin of ≥1.5 U/IU/kg/day.

         20. Subjects who have received ≥14 consecutive days of glucocorticoid therapy by oral,
             intravenous, inhaled or other routes that produce systemic effects within the past 1
             year, or who have received steroids by any route (except intra-nasal, intra-ocular,
             and topical) within the 4 weeks immediately preceding screening.

         21. Subjects diagnosed as having cancer (subjects with history of basal cell carcinoma,
             carcinoma in situ or squamous cell cancer of skin, or in remission &gt;5 years, will be
             allowed).

         22. Subjects who have donated blood or plasma in the 1 month prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Ankersen</last_name>
    <phone>+1 (724) 514-1970</phone>
    <email>michael.ankersen@mylan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keri Vaughan</last_name>
    <phone>+1 (267) 980-5015</phone>
    <email>keri.vaughan@mylan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Anderson</last_name>
    </contact>
    <investigator>
      <last_name>Paul Norwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

